Effectively nursing patients receiving aromatase inhibitor therapy.
Inhibiting estrogen production is a common means of preventing breast cancer recurrence. The aromatase inhibitors (AIs) are becoming the preferred treatment over tamoxifen as adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer. Like all adjuvant therapies, AIs have adverse events (AEs) associated with their use, many of which resemble symptoms common to menopause. Because of the greater efficacy of AIs in preventing breast cancer recurrence over tamoxifen, these AEs may be considered tolerable by many patients and often can be effectively managed and/or prevented. Educating patients about anticipated AEs may help them understand, accept, and cope with these AEs. This article reviews the AEs associated with different adjuvant AI treatments and highlights some strategies to manage them effectively. It also highlights the importance of patient education regarding AI therapy and involvement in treatment decisions, which may lead to better long-term adherence and ultimately to better outcomes.
Wengström
Y
Y
Division of Nursing, Department of Neurobiology, Care Science and Society, Karolinska Institutet, 23300, 141 83 Huddinge, Sweden. yvonne.wengstrom@ki.se
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D018771:Arthralgia / Q000139:chemically induced; D001284:Atrophy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015897:Comorbidity; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D054327:Lubricants / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009570:Nitriles / Q000627:therapeutic use; D010353:Patient Education as Topic; D011788:Quality of Life; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014621:Vagina / Q000473:pathology; D015430:Weight Gain / Q000187:drug effects
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D054327:Lubricants; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole